The World Vaccine Congress is taking place from April 21-24, 2025, in Washington, DC.

And we are delighted to offer a special discount for Immunization Economics community members.

Attendees will dive deep into topics, including breakthroughs in strategies to ensure equitable access for all communities and the global rollout of vaccines. This event covers the full spectrum of global vaccine efforts across the whole vaccine value chain; key tracks will focus on:

  • Vaccine development
  • Clinical trials
  • Regulatory policies
  • Bioprocessing manufacturing and supply chain challenges
  • Market access and immune profiling

The congress will feature speakers from Gavi, the Vaccine Alliance, PAHO, WHO, Johns Hopkins Bloomberg School of Public Health, PATH, John Snow Inc, the Gates Foundation, Center for Global Development, and more. There will be interactive networking opportunities, an exhibition showcasing the latest innovations, and workshops offering hands-on learning experiences.

COMPETITION WINNERS

We held a competition for the opportunity of presenting at the congress with travel to and from the congress sponsored, you can find out more below about the two winners who presented their work.

The World Vaccine Congress is an award-winning series of conferences and exhibitions that has grown to become the largest and most established vaccine meeting of its kind across the globe since 2000. It offers a unique opportunity to explore cutting-edge developments, forge partnerships, and drive progress in vaccine innovation.

The Congress will host 4,500+ attendees, 550+ speakers, 300+ exhibitors, and 100+ start-ups, bringing together global leaders, scientists, and industry experts across the entire vaccine landscape.

AJEET KUMAR SINGH

Immunization Technical Support Unit, Ministry of Health and Family Welfare, Government of India

Impact of Rotavirus Vaccine on Malnutrition among Children: Evidence from National Family Health Survey (NFHS) 2019-2021, India

ISABELLA IMPALLI

One Health Trust

Potential economic impact of a maternal klebsiella pneumoniae vaccine in 107 low- and middle-income countries